Free shipping on orders over €75 within the EU

VIRALEZE™ Antiviral Nasal Spray

VIRALEZE™ provides a protective moisturising barrier that traps and inactivates respiratory viruses.

Contains astodrimer sodium, shown in laboratory studies to inactivate a broad spectrum of respiratory viruses, including >99.9% of SARS-CoV-2, the virus that causes COVID-19, helping to reduce exposure to respiratory viral pathogens, but without completely avoiding the risk of infection.

Always read the label and follow the instructions for use. This medical device is a regulated health product which bears, under this regulation, the CE marking. Do not use if you have a history of sensitivity to any ingredients in the formulation. Not for use in children under the age of 12 years. See a doctor If you are pregnant or breastfeeding. Always follow recommendations from health authorities, including vaccination and good hygiene practices, such as the use of masks, physical distancing, and regular handwashing to ensure the best possible protection against respiratory viruses. For information on how to use, and for a list of warnings and precautions, click here.

VIRALEZE™ targets the area of the nose where cold and respiratory viruses first attach and start to multiply

VIRALEZE™ provides a physical moisture barrier between respiratory viruses and the nasal mucous membrane

VIRALEZE™ traps and inactivates respiratory viruses

Broad-spectrum, blocks multiple respiratory viruses, including variants of SARS-CoV-2

Acts locally and is not absorbed into the bloodstream

What is VIRALEZE™ Antiviral Nasal Spray?

VIRALEZE™ is an antiviral nasal spray that provides a physical moisture barrier between respiratory viruses and the nasal mucous membrane. The formulation contains astodrimer sodium (SPL7013), which has been shown in laboratory studies to physically trap and inactivate a broad spectrum of respiratory viruses, including >99.9% of coronavirus SARS-CoV-2, the virus that causes COVID-19, helping to reduce exposure to respiratory viral pathogens, but without completely avoiding the risk of infection.^

VIRALEZE™ is intended to be used in situations where individuals may be at risk of being exposed to respiratory viruses, and where nasal passages may become dry and irritated, such as dry climates, indoor heated/air-conditioned environments, hospitals, aged care, public transport and during air travel.

This medical device is a regulated health product which bears, under this regulation, the CE marking.

^Paull, J.R.A. et al. Virucidal and antiviral activity of astodrimer sodium against SARS-CoV-2 in vitro. Antiviral Research 2021, 191, 105089. https://doi.org/10.1016/j.antiviral.2021.105089.

Paull, J.R.A. et al. Protective effects of astodrimer sodium 1% nasal spray formulation against SARS-CoV-2 nasal challenge in K18-hACE2 mice. Viruses 2021, 13(8), 1656. https://doi.org/10.3390/v13081656

How does VIRALEZE™ work?

The nasal cavity is the primary site where SARS-CoV-2 becomes established, before spreading to the lungs.^

Mucus is naturally produced in the nose and its role is to trap foreign particles (e.g., dust or viruses) and reduce the chance of them infecting cells in the nasal cavity and entering the lungs. The mucoadhesive formula of VIRALEZE™ provides a physical moisture barrier in your nose that hydrates the nasal mucosa for protection against mucosal drying and damage, thereby supporting your body’s natural defenses against viruses.

VIRALEZE™ also contains astodrimer sodium, which has been shown in laboratory studies to physically trap and irreversibly inactivate viruses, including SARS-CoV-2, influenza and respiratory syncytial virus (RSV), helping to reduce exposure to respiratory viral pathogens, but without completely avoiding the risk of infection.

The trapped and inactivated viruses are eliminated naturally through the nasal mucus.

^Hou, Y.J. et al. SARS-CoV-2 reverse genetics reveals a variable infection gradient in the respiratory tract. Cell 2020, 182(2), 429-446.e14. https://doi.org/10.1016/j.cell.2020.05.042
†Paull, J.R.A. et al. Virucidal and antiviral activity of astodrimer sodium against SARS-CoV-2 in vitro. Antiviral Research 2021, 191, 105089. https://doi.org/10.1016/j.antiviral.2021.105089.

Paull, J.R.A. et al. Protective effects of astodrimer sodium 1% nasal spray formulation against SARS-CoV-2 nasal challenge in K18-hACE2 mice. Viruses 2021, 13(8), 1656. https://doi.org/10.3390/v13081656

VIRALEZE™ developed in Australia by Starpharma

Astodrimer sodium (also known as SPL7013) is a patented, precisely designed large molecule that cannot pass into the bloodstream and that acts locally at site of application in the nasal cavity.

Astodrimer sodium is included in products registered in >45 countries and available for sale in the UK, Europe, Japan, Southeast Asia, South Africa, Australia, and New Zealand.

Starpharma is a world leader in the development of new medical products based on its proprietary dendrimer technology.

Get your VIRALEZE™ today.